Khi sức mạnh tính toán của AI cũng bắt đầu được "chia sẻ", ai sẽ trở thành người dẫn đầu trong cuộc cạnh tranh mới này?

LianBio

company

About

LianBio aims to develop and accelerate availability of paradigm-shifting medicines to patients in China.

  • 101 - 250

Details

Last Funding Type
Series A
Last Funding Money Raised
$310M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2019
Number Of Employee
101 - 250
Operating Status
Active

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$310M
LianBio has raised a total of $310M in funding over 2 rounds. Their latest funding was raised on Oct 29, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 29, 2020 Series A $310M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
LianBio is funded by 1 investors. Pfizer are the most recent investors.
Investor Name Lead Investor Funding Round
Pfizer Series A